The FDA this week changed how it regulates insulin and other biologics, such as human growth hormone and chorionic gonadotropin, to treat them as biological products rather than drugs. The move means any insulin approved as a so-called "follow-on" is now considered a biosimilar and interchangeable with branded products, which could reduce costs.
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.